Intellia Therapeutics, Inc. is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. The company's mission is to develop curative genome editing treatments that can positively transform the lives of patients living with severe and life-threatening diseases. Intellia's pipeline includes programs focused on genetic diseases, liver diseases, and cancer. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.